In short
Moderna, Inc. (MRNA) has revenue down 39.9% to $1.9B and net income up 20.8% to -$2.8B year on year. Fisclear flags 4 high-severity risks, led by: Revenue fell 40% year-over-year — a sharp decline that signals the business is contracting significantly. How we calculate this
Valuation
HealthcareLive · Yahoo FinancePrice
$271.31
$109.8B
52-Week Range
Decision Context
Scores are balanced across the six engines. No single dimension dominates — this is consistent with a stable, mid-tier quality business.
Based on filing period ending Sept 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
Fed Funds Rate
3.88%
Accommodative
10-Year Treasury
5.13%
2026-10-01
Unemployment
4.1%
Near full employment
CPI Index
336.3
2026-09-01
M2 Money Supply
$23.4T
2026-09-01
The Federal Funds rate stands at 3.88% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 5.13%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.1%; Industrial production index is at 104.0; M2 money supply is $23.4T; CPI index stands at 336.3.
SWOT Analysis — MRNA
Inflationary BoomStrengths
Operating Cash Flow: -$1.9B (+37.6% YoY) — Negative operating cash flow — the business consumed more cash than it produced from operations.
EPS (Diluted): $-7.26 (+21.8% YoY) — Negative EPS — the company recorded a loss on a per-share basis.
Net Income: -$2.8B (+20.8% YoY) — The company posted a net loss — total expenses exceeded total revenue.
Weaknesses
Revenue: $1.9B (-39.9% YoY) — Revenue fell 40% — the company generated less from its core operations.
Total Assets: $12.3B (-12.8% YoY) — Total assets shrank 13% — the balance sheet contracted.
R&D spending is 161% of revenue — heavy investment in future growth, but also a drag on current profitability.
Stock is near its 52-week high (267.50) — the price reflects strong recent momentum, but entry risk is elevated at these levels.
Opportunities
No clear opportunities identified at this time.
Threats
Revenue fell 40% year-over-year — a sharp decline that signals the business is contracting significantly.
Revenue has declined for two consecutive years — a sustained downtrend that may signal structural or competitive headwinds.
Net loss of $2.8B — the company spent more than it earned. Investors should monitor the path to profitability.
Negative operating cash flow of $1.9B — the core business consumed more cash than it generated.
Year-over-Year Changes
Revenue
$1.9B
was $3.2B
Revenue fell 40% — the company generated less from its core operations.
Operating Cash Flow
-$1.9B
was -$3.0B
Negative operating cash flow — the business consumed more cash than it produced from operations.
EPS (Diluted)
$-7.26
was $-9.28
Negative EPS — the company recorded a loss on a per-share basis.
Net Income
-$2.8B
was -$3.6B
The company posted a net loss — total expenses exceeded total revenue.
Total Assets
$12.3B
was $14.1B
Total assets shrank 13% — the balance sheet contracted.
Risk Flags
4 high · 0 medium · 2 low- ⚠ High
Revenue fell 40% year-over-year — a sharp decline that signals the business is contracting significantly.
- ⚠ High
Revenue has declined for two consecutive years — a sustained downtrend that may signal structural or competitive headwinds.
- ⚠ High
Net loss of $2.8B — the company spent more than it earned. Investors should monitor the path to profitability.
- ⚠ High
Negative operating cash flow of $1.9B — the core business consumed more cash than it generated.
- ○ Low
R&D spending is 161% of revenue — heavy investment in future growth, but also a drag on current profitability.
- ○ Low
Stock is near its 52-week high (267.50) — the price reflects strong recent momentum, but entry risk is elevated at these levels.
Technical Signals
Daily closes · 1-year dataModerna, Inc.: common questions
Is Moderna, Inc. profitable?
No. Moderna, Inc. reported a net loss of $2.8B in its latest fiscal year (fiscal 2025).
Is Moderna, Inc.'s revenue growing?
No. Revenue fell 39.9% year on year, to $1.9B.
What is Moderna, Inc.'s P/E ratio?
Moderna, Inc. has no meaningful P/E ratio at the moment, because it lost money over the latest year. P/E only works when earnings are positive.
Does Moderna, Inc. pay a dividend?
No dividend is currently expected from Moderna, Inc., according to the latest market data.
What are the main risks for Moderna, Inc.?
Fisclear's checks flag 4 medium- or high-severity risks. The most serious: Revenue fell 40% year-over-year — a sharp decline that signals the business is contracting significantly.
Answers are generated from the figures in this report (updated 7 Nov 2026). Information, not investment advice.
Latest News
via FinnhubFiling History — MRNA
Get the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade MRNA
Links open broker research pages. Not an endorsement or recommendation.
Research Moderna, Inc.
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.